Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22912388.
- Also identified by DOI 10.1158/1078-0432.CCR-12-1952.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Anaplastic lymphoma kinase (ALK) gene rearrangements are found in approximately 5% of non-small cell lung carcinoma patients and confer sensitivity to ALK inhibitors such as crizotinib. The particular ALK fusion expressed may have an impact on protein stability and sensitivity to crizotinib, and this may underlie the heterogeneity in responses observed in the clinic.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Oncogene Proteins, Fusion
- Receptor Protein-Tyrosine Kinases